Get the app
USHealthcare

Centene Corp (CNC)

US · Healthcare · Healthcare Plans

$67.10+1.65%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$44.38B
Revenue YoY
-9.0%
Net profit
$1.09B
EPS
$2.51
EPS estimate
$0.89
Net margin
2.5%

EPS came in at 2.51 against a street estimate of 0.89 — a beat of 182.0%.

Key statistics

Market cap
$33.15B
Forward P/E
11.9
P/B
1.45
Book value
$45.67
EPS (TTM)
$-10.36
52-week high
$69.63
52-week low
$31.63
50-day MA
$65.55
200-day MA
$51.35
Beta
1.11

Analyst view

Analysts rate Centene Corp a buy (10 buy, 9 hold, 0 sell out of 19) with an average price target of $71.78.

From the latest earnings call · 2026-07-28

CONFIDENT CNC beat Q2 EPS at $2.51, raised full-year guidance to >$4.80 (vs. >$3.40 prior). Marketplace margin recovery to 4.5–5% on favorable risk adjustment; Medicaid rates improved to 5% but membership attrition higher; Medicare PDP >3% margin (vs. 2%). Enterprise optimization underway. Q2 2026 Call structured by business line, not geography. Analysts pressed timing of Medicaid margin recovery amid OB3, acuity shifts, and rate lag. Management emphasized scope/scale narrower than PHE redetermination, impactability via community programs, and state partnership on mid-cycle adjustments. Marketplace success attributed to data-driven diagnosis and conservative positioning ahead of June Wakely confirmation. 2026-07-28…

Full summary in the app.

Shareholding

Insiders
0.39%
Institutions
101.72%

Largest institutional holders

FundStake
BlackRock Inc8.06%
AQR Capital Management LLC6.80%
Vanguard Capital Management, LLC6.32%
State Street Corp4.38%
Vanguard Portfolio Management, LLC4.38%
Wellington Management Company LLP2.69%
Geode Capital Management, LLC2.63%
Harris Associates L.P.2.25%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 2026
CENTENE CORPORATION – FORM 8-K SUMMARY September 16, 2026 --- HEADLINE NUMBERS • Full year 2026 GAAP diluted EPS guidance: greater than $3.11 • Ful
2026-09-16
Board / officer change · Q3 2026
CENTENE CORPORATION (CNC) – FORM 8-K SUMMARY HEADLINE NUMBERS • 2026 adjusted diluted EPS guidance: greater than $4.80 (reaffirmed August 17, 2026)
2026-08-17
Company announcement · Q3 2026
CENTENE CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Centene Corporation announced a partial redemption of $500,000,000 in aggregate principal
2026-07-29
Quarterly report · Q2 2026
CENTENE CORPORATION – Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Net earnings (6 months): $2,632 million (attributable to Centene), up from $1,058
2026-07-28
Results announced · Q3 2026
CENTENE CORPORATION Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 GAAP Diluted EPS: $2.19 | Adjusted Diluted EPS: $2.51 • Total revenues: $53.5
2026-07-28
Board / officer change · Q2 2026
CENTENE CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 9 to 10 directors effective June 19, 2026 • One new director app
2026-06-22
Quarterly report · Q1 2026
CENTENE CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net earnings attributable to Centene: $1,541 million (Q1 2026) vs. $1,311 million (Q1
2026-04-28
Proxy statement · Q2 2026
CENTENE CORPORATION PROXY STATEMENT SUMMARY EXECUTIVE PAY • CEO Sarah M. London's 2025 total compensation: Not specified in document. The proxy stat
2026-03-26

Readable in the app.

Deals & corporate news

AnnouncementDate
2026 full year guidance provided as forward-looking statement
This 8-K filing contains only boilerplate legal language and forward-looking statement disclaimers from Centene Corporation, a major health insurance company. No actual business events, fina
2026-09-16
2026 full year guidance provided; CFO transition timeline and terms announced
Centene Corporation filed an 8-K disclosing a CFO transition and issuing 2026 full-year financial guidance. The specific terms and timeline of the CFO change are referenced in attached exhib
2026-08-17
Reaffirms 2026 full year GAAP and adjusted EPS guidance
Centene Corporation, a major health insurance company, announced that senior management will meet with investors during the week of February 23, 2026. The company reaffirmed its previously a
2026-02-23
Fourth quarter and full year 2025 financial results with 2026 guidance
Centene Corporation filed an 8-K on February 6, 2026, disclosing its financial results for Q4 2025 and full year 2025, along with 2026 guidance. The filing itself contains no specific financ
2026-02-06

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Centene Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.